Owlet, Inc.

NYSE:OWLT

Medical - Devices

Healthcare
$3.67 +9.76%

+$0.46 today

Market cap
$107.24M
Beta
1.86
P/E (TTM)
-0.4
EPS (TTM)
-$12.67
52W Low $4.19High $16.94

Volume 0.64M

Average 0.24M

OWLT Interest Expense

Cost of servicing the company's debt during the period.

Owlet, Inc.NYSE: OWLT

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense dips below year-ago levels

Q1 FY2026 interest expense of $683K fell 31.1% year over year, behind the +26.0% change in trailing-twelve-month interest expense. Sequentially, it rose 16.2% from the prior quarter. Over 3 fiscal years it compounded at +45.7% a year.

Context

  • Interest expense amounted to 3.2% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -31.1% toward the trailing-twelve-month pace of +26.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$683K+16.2% QoQ
Last fiscal yearDec 2025
$3.42M+109.7% YoY
LTMMar 2026
$3.11M+26.0% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-31.1%——
1 year+109.7%——
3-year CAGR+45.7%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
3.42M USD
Year-over-year change
+109.7%
4-year CAGR
-40.8%

Interest Expense vs competitors

How OWLT compares with its peers on the latest reported figures

  • OWLT's LTM Mar 2026 interest expense of $3.11M is the highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +26.0% is the 2nd highest of 5, against a peer median of -15.7%.
  • Interest expense amounts to 2.9% of revenue for OWLT, versus a peer median of 0.0%.
OWLT Competitors Peer median
Interest Expense for OWLT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OWLTOwlet, Inc.LTM Mar 2026$3.11M +26.0%+45.7%2.9%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$1.87M ——5.4%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$1.36M +128.9%-32.0%—
AVRAnteris Technologies Global Corp.LTM Mar 2026$74K -18.3%-51.7%4.0%
LUCDLucid Diagnostics Inc.LTM Mar 2026$20K -13.0%+40.1%0.4%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
MXCTMaxCyte, Inc.LTM Mar 2026$0 ——0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 -100.0%——
LNSRLENSAR, Inc.LTM Mar 2026$0 ——0.0%
CRDFCardiff Oncology, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding OWLT) $0-15.7%-32.0%0.0%

Competitors are the stored peer set for OWLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75.84M69.2M54.01M78.06M105.71M
Cost of Revenue40.78M45.89M31.42M38.75M52.18M
Gross Profit35.06M23.31M22.59M39.31M53.53M
Gross Margin46.2%33.7%41.8%50.4%50.6%
Research & Development21.43M27.9M10.35M9.8M14.08M
Selling, General & Admin69.42M80.04M40.87M49.73M47.72M
Operating Expenses90.85M107.93M51.22M59.53M61.79M
Depreciation & Amortization1.13M2.67M2.21M1.38M590K
EBITDA(42.71M)(75.53M)(27.49M)(9.47M)(35.64M)
EBITDA Margin-56.3%-109.1%-50.9%-12.1%-33.7%
Operating Income(55.79M)(84.62M)(28.63M)(20.22M)(8.26M)
Operating Margin-73.6%-122.3%-53.0%-25.9%-7.8%
Interest Income00000
Interest Expense27.83M1.1M3.19M1.63M3.42M
Other Income / Expenses(15.88M)5.31M(4.26M)7.74M(31.39M)
Income Before Tax(71.67M)(79.31M)(32.89M)(12.48M)(39.65M)
Pre-Tax Margin-94.5%-114.6%-60.9%-16.0%-37.5%
Income Tax Expense31K29K10K54K28K
Net Income(71.7M)(79.34M)(32.9M)(12.54M)(39.68M)
Net Margin-94.5%-114.6%-60.9%-16.1%-37.5%
EPS (Basic)(12.47)(9.97)(4.53)(0.83)(2.24)
EPS (Diluted)(12.47)(9.97)(4.53)(0.83)(2.24)
Weighted Avg Shares7.87M7.95M8.28M15.11M562.5M
Weighted Avg Shares (Diluted)7.87M7.95M8.28M15.11M562.5M

Owlet, Inc.

NYSE:OWLT

Intrinsic Alpha fair value

Locked

Current Price

$3.67

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.